Females on SD had a slight body weight reduction compared to their starting weight, which was greater than the body-weight change seen in males on SD ( p = 0.022, Cohens d = 0.950)
[1] [3] Clear instructions should be provided regarding when to contact healthcare providers, including signs of severe adverse effects or MS relapse
Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s, are becoming increasingly widespread, with the most notable examples including Ozempic, Wegovy, and Saxenda
Prepare to give yourself a shot
Bioavailability is critical
Individual metabolic response, adherence, and lifestyle factors play a larger role in real-world outcomes than trial averages suggest